Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Goes Big On Generic Injectables With Acquisition Of 15 Products From India’s Claris

This article was originally published in PharmAsia News

Executive Summary

AHMEDABAD, India - Two months after Pfizer signed a comprehensive in-licensing agreement for more than 50 oral and injectable products with Aurobindo Pharma, the U.S. company has entered into another deal, with India's Claris Lifesciences, to commercialize 15 products covering a broad range of therapeutic areas including anti-infectives and pain drugs

You may also be interested in...



Off FDA’s Hook, India’s Claris Moves To Link Up Again With Pfizer, But Falters

Claris has been through grueling times implementing corrections mandated by U.S. FDA and set its sights on reclaiming a valuable supply deal, but Pfizer has distanced itself from the company.

Off FDA’s Hook, India’s Claris Moves To Link Up Again With Pfizer, But Falters

Claris has been through grueling times implementing corrections mandated by U.S. FDA and set its sights on reclaiming a valuable supply deal, but Pfizer has distanced itself from the company.

With Emerging Markets On Radar, AstraZeneca Close To Teaming Up With India's Intas For Sourcing Sterile And Oncology Drugs

MUMBAI - AstraZeneca is days away from signing an agreement with India's Intas Pharmaceuticals for supplies of a large number of generic sterile and oncology products to be sold in emerging markets. The deal will likely cover as many as 45 products to be sold in nine markets, with the scope for expanding the range of products further

Related Content

UsernamePublicRestriction

Register

SC071710

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel